NHS National Pharmaceuticals Transition 2021_3
A Contract Award Notice
by THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND)
- Source
- Find a Tender
- Type
- Framework (Goods)
- Duration
- not specified
- Value
- £1
- Sector
- HEALTH
- Published
- 04 Nov 2021
- Delivery
- not specified
- Deadline
- n/a
Concepts
Location
United Kingdom: Please refer to Document 3, Schedule 8 in the ITO Documents for the list of purchasing points
1 buyer
36 suppliers
- Glenmark Pharmaceuticals Europe Watford
- Zentiva Pharma Guildford
- Drreddys Laboratories Beverley
- Brown & Burk Uxbridge
- Thornton & Ross Huddersfield
- Medac Pharma Stirling
- Kensington Pharma Preston
- Mylan Hatfield
- Morningside Pharmaeuticals Loughborough
- Torbay Pharmaceuticals Paignton
- Ranbaxy Hayes
- Aspire Pharma Petersfield
- Kent Pharma Ashford
- Pfizer Tadworth
- Panpharma Liverpool
- Teva Castleford
- Drugsrus Harrow
- Alturix Milton Keynes
- Colonis Pharma Weybridge
- Ambe Medical Group Edenbridge
- Aspen Pharmacare Maidenhead
- CST Pharma Walsall
- Macure Pharma Aps Copenhagen
- Accord Barnstaple
- Lucane Pharma Ankeveen
- Mercury Pharmaceuticals London
- Wockhardt Wrexham
- Aguettant Bristol
- Roche Products Welwyn Garden City
- Seacross Pharmaceuticals London
- Laboratorio Reig Jofre Bideford
- Consilient Health Richmond upon Thames
- Day Lewis Medical Croydon
- Napp Pharmaceuticals Cambridge
- Cipla Eu London
- Amarox Harrow
Description
NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633
Lot Division
1 | Hospital Only Products – CESW region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products:LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition:LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) |
2 | Hospital Only Products – LSNE region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents |
3 | Hospital Only Products – NWLN region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) |
4 | Oral (plus non-parenteral) products: All regions NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) |
5 | Transition Products – CESW region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) |
6 | Transition Products – LSNE region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) |
7 | Transition Products – NWLN region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) |
Award Detail
1 | Glenmark Pharmaceuticals Europe (Watford)
|
2 | Zentiva Pharma (Guildford)
|
3 | Drreddys Laboratories (Beverley)
|
4 | Brown & Burk (Uxbridge)
|
5 | Thornton & Ross (Huddersfield)
|
6 | Medac Pharma (Stirling)
|
7 | Kensington Pharma (Preston)
|
8 | Mylan (Hatfield)
|
9 | Morningside Pharmaeuticals (Loughborough)
|
10 | Torbay Pharmaceuticals (Paignton)
|
11 | Ranbaxy (Hayes)
|
12 | Aspire Pharma (Petersfield)
|
13 | Kent Pharma (Ashford)
|
14 | Pfizer (Tadworth)
|
15 | Panpharma (Liverpool)
|
16 | Teva (Castleford)
|
17 | Drugsrus (Harrow)
|
18 | Alturix (Milton Keynes)
|
19 | Colonis Pharma (Weybridge)
|
20 | Ambe Medical Group (Edenbridge)
|
21 | Aspen Pharmacare (Maidenhead)
|
22 | CST Pharma (Walsall)
|
23 | Macure Pharma Aps (Copenhagen)
|
24 | Accord (Barnstaple)
|
25 | Lucane Pharma (Ankeveen)
|
26 | Mercury Pharmaceuticals (London)
|
27 | Wockhardt (Wrexham)
|
28 | Aguettant (Bristol)
|
29 | Roche Products (Welwyn Garden City)
|
30 | Teva (Castleford)
|
31 | Drugsrus (Harrow)
|
32 | Colonis Pharma (Weybridge)
|
33 | Macure Pharma Aps (Copenhagen)
|
34 | Accord (Barnstaple)
|
35 | Seacross Pharmaceuticals (London)
|
36 | Laboratorio Reig Jofre (Bideford)
|
37 | Consilient Health (Richmond upon Thames)
|
38 | Drugsrus (Harrow)
|
39 | Alturix (Milton Keynes)
|
40 | Colonis Pharma (Weybridge)
|
41 | Macure Pharma Aps (Copenhagen)
|
42 | Glenmark Pharmaceuticals Europe (Watford)
|
43 | Day Lewis Medical (Croydon)
|
44 | Napp Pharmaceuticals (Cambridge)
|
45 | Cipla Eu (London)
|
46 | Mylan (Hatfield)
|
47 | Teva (Castleford)
|
48 | Amarox (Harrow)
|
49 | Teva (Castleford)
|
50 | Drreddys Laboratories (Beverley)
|
51 | Cipla Eu (London)
|
52 | Mylan (Hatfield)
|
53 | Amarox (Harrow)
|
54 | Teva (Castleford)
|
55 | Accord (Barnstaple)
|
56 | Thornton & Ross (Huddersfield)
|
57 | Cipla Eu (London)
|
58 | Amarox (Harrow)
|
59 | Teva (Castleford)
|
Renewal Options
option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.
Award Criteria
price | _ |
CPV Codes
- 33600000 - Pharmaceutical products
Indicators
- Options are available.
Other Information
** PREVIEW NOTICE, please check Find a Tender for full details. **
Reference
- ocds-h6vhtk-02b7a6
- FTS 027695-2021